Your Sorted CME/CE Activities


Independent Conference Coverage from the American Association for the Study of Liver Diseases (AASLD)* 2017
Certified CME/CNE Activity - Research Roundup
Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH), are common causes of chronic liver disease with an increasing worldwide prevalence. The condition is associated with increased mortality related to cardiovascular disease, malignancy, and liver disease. No single treatment approach has proved universally applicable to the general population with NASH. Several promising drug therapies for NASH are in clinical trials and are anticipated to pave the way for new and more effective treatment options.

This Research Roundup® will discuss the need for newer drugs/approaches for NASH to improve liver and other outcomes in patients with NAFLD.
Review Research Roundup newsletter. Claim AMA or ANCC credit/contact hour(s) after completion of a brief Post-Test/Evaluation.
Kris V. Kowdley
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, FAASLD
Director, Liver Care Network and Organ Care Research
Swedish Medical Center, Seattle, Washington
Clinical Professor, Washington State University

*This conference coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of AASLD 2017.
20
Supported by an independent educational grant from
Gilead Sciences Medical Affairs
1300
Expired Activity
Mini Module
6167
../../../PR_Files/PrintArticles/Images/Nash_2017/Banner_Nash_2017_2.gif
LiverDisease